LEP and melanoma: The absence of effects on weight and food intake suggested that the central actions of leptin were not disrupted by low-dose 2.17-mAlb although the low-dose nanobody administered adjacent to the tumor was sufficient to decrease the growth of a highly aggressive melanoma by 33%.